Randomised controlled trial: Phase 3 trial with the RTS,S/AS01 malaria vaccine shows protection against clinical and severe malaria in infants and children in Africa

Evidence-Based Medicine

Volumn 20, Issue 1, 2015, Pages 9-

  Targett, Geoffrey ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; RTS S AS01 VACCINE; UNCLASSIFIED DRUG;

AFRICA; ARTICLE; CHILD; CHILD HOSPITALIZATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; INFANT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; PARASITE LOAD; PHASE 3 CLINICAL TRIAL; TREATMENT RESPONSE; VACCINATION; MALARIA, FALCIPARUM; STANDARDS;

HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; VACCINATION;

EID: 84922019893     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebmed-2014-110089     Document Type: Article

References (8)

1. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014;11:e1001685.
2. World Health Organization. World Malaria Report 2013. Geneva: World Health Organization, 2013.
3. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. New Eng J Med 2014;371:411-23.
4. Protopopoff N, Matowo J, Malima R, et al. High level of resistance in the mosquito Anopheles gambiae to pyrethroid insecticides and reduced susceptibility to bendiocarb in north-western Tanzania. Malar J 2013;12:149.
5. Hill AVS. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 2011;366:2806-14.
6. Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013;341:1359-65.
7. Douglas AD, Williams AR, Knuepfer E, et al . Neutralization of Plasmodium falciparum by antibodies against PfRH5. J Immunol 2014;192:245-58.
8. Theisen M, Roeffen W, Singh SK, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 2014;32:2623-30.